BioCryst Pharmaceuticals (BCRX)
(Delayed Data from NSDQ)
$8.28 USD
+0.03 (0.36%)
Updated Sep 4, 2024 04:00 PM ET
After-Market: $8.28 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
BioCryst Pharmaceuticals (BCRX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$14.27 | $30.00 | $7.00 | 72.97% |
Price Target
Based on short-term price targets offered by 11 analysts, the average price target for BioCryst Pharmaceuticals comes to $14.27. The forecasts range from a low of $7.00 to a high of $30.00. The average price target represents an increase of 72.97% from the last closing price of $8.25.
Analyst Price Targets (11)
Broker Rating
BioCryst Pharmaceuticals currently has an average brokerage recommendation (ABR) of 1.36 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 11 brokerage firms. The current ABR compares to an ABR of 1.50 a month ago based on 12 recommendations.
Of the 11 recommendations deriving the current ABR, eight are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 72.73% and 18.18% of all recommendations. A month ago, Strong Buy made up 66.67%, while Buy represented 16.67%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 8 | 8 | 8 | 8 | 8 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 1 | 1 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.36 | 1.36 | 1.50 | 1.50 | 1.50 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/6/2024 | Cowen & Co. | Stacy Ku | Strong Buy | Strong Buy |
8/6/2024 | Not Identified | Not Identified | Hold | Hold |
8/6/2024 | H.C. Wainwright & Co. | Andrew S Fein | Strong Buy | Strong Buy |
8/6/2024 | Evercore Partners | Liisa A Bayko | Strong Buy | Strong Buy |
8/6/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
8/6/2024 | JMP Securities | Jonathan Wolleben | Strong Buy | Strong Buy |
8/5/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/23/2024 | Piper Sandler | Christopher Raymond | Strong Buy | Strong Buy |
4/10/2024 | Needham & Company | Serge Belanger | Moderate Buy | Moderate Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.36 |
ABR (Last week) | 1.36 |
# of Recs in ABR | 11 |
Average Target Price | $14.27 |
LT Growth Rate | 40.40% |
Industry | Medical - Drugs |
Industry Rank by ABR | 99 of 253 |
Current Quarter EPS Est: | -0.09 |